A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

Study Identifier
150998-005
CT.gov Identifier
EudraCT Identifier
EUCTIS ID
Not available
For general inquiries, please contact
Study Complete

Results Available

Statistical Analysis Plan
Available Language(s): English
Protocol
Available Language(s): English

Study Details

Medical Condition
  • Macular Degeneration - Other
  • Study Drug
  • Abicipar Pegol
  • Ranibizumab
  • Phase
    Phase 3
    Sex
    Female & Male
    Age
    50+ years

    Protocol Summary

    This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

    Study Locations

    Location
    Status
    Location
    Retinal Research Institute, LLC
    Phoenix, Arizona, United States, 85014
    Status
    Not applicable
    Location
    Associated Retina Consultants, Ltd.
    Phoenix, Arizona, United States, 85020
    Status
    Not applicable
    Location
    Arizona Retina and Vitreous Consultants
    Phoenix, Arizona, United States, 85021
    Status
    Not applicable
    Location
    Retina Associates Southwest, P.C.
    Tucson, Arizona, United States, 85710
    Status
    Not applicable
    Location
    The Retina Partners
    Encino, California, United States, 91436
    Status
    Not applicable
    Location
    Retina Consultants of Orange County
    Fullerton, California, United States, 92835
    Status
    Not applicable
    Showing {first} - {last} of {total} Results